Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.46 |
| ▸ | PYGL | P06737 | 3/20 | 0.46 |
| ▸ | PYGM | P11217 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3712334 | 1.00 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL6302580 | 1.00 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL8946124 | 1.00 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL30858806 | 1.00 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL18927294 | 1.00 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL29407009 | 1.00 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL30701888 | 1.00 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL18927292 | 1.00 | PYGB (0.46) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL23017509 | 0.93 | PYGB (0.39) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL16389053 | 0.93 | PYGB (0.39) | PYGBPYGLPYGMLMNAGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008103470-A2 | ONCOGENIC-RAS-SIGNAL DEPENDENT LETHAL COMPOUNDS | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-08-28 | — | — | WO | claimed |
| JP-9309896-A | — | — | None | — | — | JP | disclosed |
| CN-118286432-B | Application of acetaldehyde dehydrogenase 1 family member A3 and inhibitor thereof in preparation of chronic heart failure drugs | 中国药科大学 | 2026-02-27 | — | — | CN | disclosed |
| CN-119950518-A | Application of deoxycholic acid and analogues thereof | 皖南医学院 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025059302-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT AND MODULATION OF ACUTE AND CHRONIC SYMPTOMS OF MITOCHONDRIAL DISEASE AND DYSFUNCTION | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119553760-A | Caravan type public toilet and control method | 张英华 | 2025-03-04 | — | — | CN | disclosed |
| CN-119367504-A | Application of ubenimex in preparation of drug for inhibiting Parthanatos cell death | 皖南医学院 | 2025-01-28 | — | — | CN | disclosed |
| CN-115671104-B | Application of compound in preparation of medicine for preventing or treating ischemic cerebral apoplexy | 中国医学科学院药物研究所 | 2024-11-05 | — | — | CN | disclosed |
| CN-116254278-B | Target sequence of RNA virus and application thereof | 上海市公共卫生临床中心 | 2024-10-01 | — | — | CN | disclosed |
| CN-118680939-A | Application of medroxyprogesterone and analogue thereof in preparation of medicines for inhibiting Parthanatos cell death | 皖南医学院 | 2024-09-24 | — | — | CN | disclosed |
| CN-113693991-A | Composition for effectively relieving wrinkle generation and preparation method and application thereof | 上海梦希生物科技有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-106212614-A | A kind of cookies of early prevention and treatment type 2 diabetes mellitus and preparation method thereof | 史华民 | 2016-12-14 | — | — | CN | disclosed |
| US-8546421-B1 | Oncogenic-RAS-signal dependent lethal compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100081654-A1 | Oncogenic-RAS-signal dependent lethal compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| WO-2008103470-A2 | ONCOGENIC-RAS-SIGNAL DEPENDENT LETHAL COMPOUNDS | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-08-28 | — | — | WO | disclosed |
| CN-1283391-A | Extracted liquor for disinfection | YE PUSEN (CN) | 2001-02-14 | — | — | CN | disclosed |
| JP-H09309896-A | GLYCOSIDATION OF COLCHICINE DERIVATIVE AND ITS FORMED PRODUCT | INDENA SPA | 1997-12-02 | — | — | JP | disclosed |
| US-5587442-A | Polyglycomers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1996-12-24 | — | — | US | disclosed |
| WO-1996020236-A1 | POLYGLYCOMERS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-07-04 | — | — | WO | disclosed |
| US-5385750-A | Improving the pesticide coating by applying a mixture of fatty alcohol glycoside or ethylene oxide fatty alcohol adduct glycoside wetting agents and a fatty alcohol | HENKEL CORPORATION (US) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081654-A1 | Oncogenic-RAS-signal dependent lethal compounds | HRAS, KRAS, NRAS | PYGB 4055/4885PYGL 1834/4885PYGM 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.